Viatris VTRS Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Net Sales by Business | |||||
| Developed Markets Segment | $8.55B-4.6% | $8.96B-3.4% | $9.28B-5.2% | $9.79B-6.1% | |
| Emerging Markets Segment | $2.22B-1.9% | $2.26B-11.8% | $2.56B-2.8% | $2.64B-16.1% | |
| Greater China | $2.33B+7.6% | $2.17B+0.3% | $2.16B-1.9% | $2.2B-0.5% | |
| Japan, Australia and New Zealand Segment | $1.2B-11.3% | $1.35B-5.3% | $1.43B-12.7% | $1.63B-19.4% | |
| Other revenues by Business | |||||
| Emerging Markets | $7.5M-22.7% | $9.7M-14.2% | $11.3M-47.2% | $21.4M— | |
| Greater China | $0-100% | $1.3M— | $0— | $0— | |
| JANZ | $3.9M+11.4% | $3.5M+218% | $1.1M-21.4% | $1.4M— | |
| Segment profit by Business | |||||
| Emerging Markets | $940.4M+0.7% | $934.1M-14.5% | $1.09B-9.5% | $1.21B— | |
| Greater China | $1.57B+11.8% | $1.4B-1.6% | $1.43B-5.7% | $1.51B— | |
| JANZ | $304.5M-20.5% | $383.1M-26.7% | $522.9M-21.4% | $665.5M— | |
| Selling, general and administration by Business | |||||
| Developed Markets Segment | $967.9M-11.8% | $1.1B-2.4% | $1.12B+27.2% | $884M— | |
| Emerging Markets Segment | $310M0.0% | $309.9M-12.7% | $354.8M+3.4% | $343.1M— | |
| Greater China | $512.2M-1.2% | $518.5M-1.8% | $528.1M+7.1% | $492.9M— | |
| Japan, Australia and New Zealand Segment | $158.9M-5.6% | $168.3M-5.0% | $177.2M-8.7% | $194M— | |
| Cost of Sales by Business | |||||
| Emerging Markets | $967.2M-4.8% | $1.02B-8.9% | $1.12B+2.7% | $1.09B— | |
| Greater China | $250.6M+2.0% | $245.7M+19.6% | $205.5M+5.0% | $195.8M— | |
| JANZ | $734.3M-8.0% | $798.3M+10.0% | $725.5M-6.3% | $774.3M— | |
| Foreign currency translation by Business | |||||
| Developed Markets Segment | $547.1M+246% | -$374M— | —— | $146M— | |
| Greater China | $11.7M— | —— | —— | —— | |
| Goodwill, Impaired, Accumulated Impairment Loss by Business | |||||
| Developed Markets Segment | $12.76B+243% | $3.72B+78.3% | $2.08B+35.3% | $1.54B0.0% | |
| Emerging Markets Segment | $2B+705% | $248M+9.3% | $227M+94.0% | $117M— | |
| Japan, Australia and New Zealand Segment | $2.61B+141% | $1.08B— | —— | —— | |
| Goodwill by Business | |||||
| Developed Markets Segment | $19.79B-28.8% | $27.82B-6.4% | $29.7B-0.1% | $29.74B-15.7% | |
| Emerging Markets Segment | $3.19B-31.8% | $4.68B-9.2% | $5.15B-9.2% | $5.68B-13.2% | |
| Greater China | $3.71B+0.3% | $3.7B-1.3% | $3.75B-1.2% | $3.8B+9.8% | |
| Japan, Australia and New Zealand Segment | $0-100% | $1.52B-42.7% | $2.65B-4.4% | $2.77B-13.7% | |
| Net Sales by Product | |||||
| Brands | $9.18B-0.2% | $9.2B-6.1% | $9.8B-0.9% | $9.89B-8.8% | |
| Celebrex ® | $272.9M-4.4% | $285.6M-13.6% | $330.6M-2.2% | $338M-1.9% | |
| Creon ® | $365.8M+11.5% | $328.2M+7.6% | $304.9M+0.3% | $304M-1.9% | |
| Dymista ® | $163.6M-13.0% | $188M-6.0% | $200M+11.2% | $179.9M+7.1% | |
| Effexor ® | $257.7M+1.9% | $252.9M-3.8% | $262.9M-6.0% | $279.6M-11.7% | |
| EpiPen® Auto-Injectors | $469.7M+19.8% | $392M-11.4% | $442.2M+17.0% | $378M-3.5% | |
| Generics | $5.07B-7.8% | $5.49B-1.7% | $5.59B-11.7% | $6.33B-9.2% | |
| Lipitor | $1.55B+5.5% | $1.47B-5.8% | $1.56B-4.6% | $1.64B-1.7% | |
| Lyrica ® | $487M-1.7% | $495.4M-11.0% | $556.5M-10.8% | $623.9M-14.4% | |
| Norvasc | $709.9M+5.4% | $673.3M-8.1% | $732.4M-5.5% | $775.1M-6.0% | |
| Viagra ® | $408.2M+3.2% | $395.6M-7.7% | $428.8M-6.6% | $458.9M-14.0% | |
| Xalabrands | $158.4M-4.8% | $166.4M-13.9% | $193.2M-1.0% | $195.1M-13.7% | |
| Xanax ® | $139.9M-3.5% | $145M-6.3% | $154.8M-1.1% | $156.5M-15.8% | |
| Yupelri ® | $266.9M+11.9% | $238.5M+8.0% | $220.8M+9.2% | $202.2M+24.9% | |
| Zoloft ® | $254.9M+8.1% | $235.7M0.0% | $235.7M-4.3% | $246.2M-13.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Viatris break its business down?
- Viatris (VTRS) reports net sales by business across 4 parts — Developed Markets Segment, Emerging Markets Segment, Greater China and Japan, Australia and New Zealand Segment. Each is extracted from the segment footnotes and tracked over time.
- Where does Viatris's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Viatris's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
